Table VIII.
Percentages of intervention in included studies.
| MS rank | MS mOS | mOS-ITC | Author, year | ITC (%) | TKI (%) | SCT (%) | WBRT (%) | SC (%) | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.0 mo | 3.0 mo | Gwak et al, 2013 | 100.0 | 27.6c | 22.9c | 28.6c | – | (23) |
| 2 | 3.0 mo | 18.0 moa | Morris et al, 2012 | 6.0 | 14.0 | 16.0 | 45.0 | 30.0 | (10) |
| 3 | 14 wks | 17 wks | Lee et al, 2013 | 73.2 | 16.1 | 16.8 | 43.7 | 13.4 | (1) |
| 4 | 3.6 mo | – | Umemura et al, 2012 | 29.7 | 56.0 | 29.9 | 23.1 | 25.3 | (12) |
| 5 | 4.3 mo | – | Park et al, 2012 | 96.0 | 28.0 | 24.0 | 42.2c | – | (24) |
| 6 | 5.0 mo | 5.0 mo | Chamberlain et al, 1998 | 100.0 | 0.0 | 37.5c | 28.1d | 0.0 | (7) |
| 7 | 6.0 mo | 6.0 mo | Present study | 100.0 | 0.0 | 24.0c | 18.0d | 0.0 | |
| 8 | 7.0 mo | 7.0 mo | Nakagawa et al, 1999b | 100.0 | 0.0 | 0.0e | 0.0e | 0.0 | (21) |
| 9 | 7.5 mo | 7.5 mo | Present studyc | 100.0 | 0.0 | 0.0e | 0.0e | 0.0 | |
| 10 | 8.0 mo | 8.0 mo | Nakagawa et al, 1996b | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | (22) |
a
Only 6 patients received ITC
b
Also calculated in the present study
c
concurrent with ITC
d
prior to ITC
e
Some patients in this study received WBRT or SCT prior to ITC, but the start point for calculating survival is the onset of ITC. MS, median survival; mOS, MS of all the patients; mOS-ITC, MS related to ITC; ITC, intrathecal chemotherapy; SCT, systemic chemotherapy; WBRT, whole-brain radiotherapy; SC, support care; Ref., reference; mo, months; wks, weeks; -, unavailable.